Prognostic factors other than the performance status and age for glioblastoma multiforme: A single-institution experience

Journal of B.U.ON.

Volumn 14, Issue 2, 2009, Pages 211-218

  Caloglu, Murat ^a   Yurut Caloglu, V ^a   Karagol, H ^a   Bayir Angin, G ^a   Turan, F N ^a   Uzal, C ^a  

^a TRAKYA UNIVERSITY   (Turkey)

Author keywords

Chemotherapy; Gender; Glioblastoma multiforme; Prognostic factors; Radiotherapy; Survival

Indexed keywords

TEMOZOLOMIDE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SEX DIFFERENCE; TREATMENT DURATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67651027830     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Athanassiou H, Synodinou M, Maragoudakis E et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 2005; 23: 2372-2377. (Pubitemid 46218731)
2. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979; 5: 1725-1731.
3. Walker MD, Alexander E, Jr., Hunt WE et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978; 49: 333-343.
4. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996. (Pubitemid 40349501)
5. Combs SE, Gutwein S, Schulz-Ertner D et al. Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. Strahlenther Onkol 2005; 181: 372-377. (Pubitemid 40875261)
6. Mineo JF, Bordron A, Baroncini M et al. Prognostic factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients. Acta Neurochir (Wien) 2007; 149: 245-253. (Pubitemid 46365411)
7. Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J. Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. J Cancer Res Clin Oncol 2003; 129: 477-484. (Pubitemid 37056155)
8. Baxendine-Jones J, Campbell I, Ellison D. p53 status has no prognostic significance in glioblastomas treated with radiotherapy. Clin Neuropathol 1997; 16: 332-336. (Pubitemid 27483785)
9. Bouvier-Labit C, Chinot O, Ochi C, Gambarelli D, Dufour H, Figarella-Branger D. Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropathol Appl Neurobiol 1998; 24: 381-388. (Pubitemid 28479484)
10. Stark AM, Nabavi A, Mehdorn HM, Blomer U. Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg Neurol 2005; 63: 162-169; discussion 169. (Pubitemid 40174904)
11. Ulutin C, Fayda M, Aksu G et al. Primary glioblastoma multiforme in younger patients: a single-institution experience. Tumori 2006; 92: 407-411. (Pubitemid 44861776)
12. Walker MD, Green SB, Byar DP et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303: 1323-1329.
13. Simmons ML, Lamborn KR, Takahashi M et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 2001; 61: 1122-1128.
14. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 2001; 19: 509-518.
15. Simpson JR, Horton J, Scott C et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993; 26: 239-244. (Pubitemid 23156970)
16. Salcman M. Resection and reoperation in neuro-oncology. Rationale and approach. Neurol Clin 1985; 3: 831-842.
17. Quigley MR, Maroon JC. The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery 1991; 29: 385-388; discussion 388-389.
18. Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95: 190-198. (Pubitemid 32799739)
19. Silbergeld DL, Rostomily RC, Alvord EC, Jr. The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adults. J Neurooncol 1991; 10: 179-185.
20. Brandes AA. State-of-the-art treatment of high-grade brain tumors. Semin Oncol 2003; 30: 4-9. (Pubitemid 38199156)
21. Gehan EA, Walker MD. Prognostic factors for patients with brain tumors. Natl Cancer Inst Monogr 1977; 46: 189-195. (Pubitemid 8342522)
22. Miller PJ, Hassanein RS, Giri PG, Kimler BF, O'Boynick P, Evans RG. Univariate and multivariate statistical analysis of high-grade gliomas: the relationship of radiation dose and other prognostic factors. Int J Radiat Oncol Biol Phys 1990; 19: 275-280. (Pubitemid 20299018)
23. Curran WJ, Jr, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85: 704-710. (Pubitemid 23133591)
24. Andersen AP. Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radiol Oncol Radiat Phys Biol 1978; 17: 475-484.
25. Kristiansen K, Hagen S, Kollevold T et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981; 47: 649-652.
26. Nelson DF, Diener-West M, Horton J, Chang CH, Schoenfeld D, Nelson JS. Combined modality approach to treatment of malignant gliomas - re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr 1988: 279-284. (Pubitemid 18048001)
27. Arslan M, Karadeniz AN, Aksu G et al. Postoperative hypofractionated radiotherapy in glioblastoma multiforme. J BUON 2006; 11: 39-42. (Pubitemid 43732748)
28. Grossman SA, Batara JF. Current management of glioblastoma multiforme. Semin Oncol 2004; 31: 635-644.
29. Burnet NG, Jena R, Jefferies SJ, Stenning SP, Kirkby NF. Mathematical modelling of survival of glioblastoma patients suggests a role for radiotherapy dose escalation and predicts poorer outcome after delay to start treatment. Clin Oncol (R Coll Radiol) 2006; 18: 93-103. (Pubitemid 43169136)
30. Do V, Gebski V, Barton MB. The effect of waiting for radiotherapy for grade III/IV gliomas. Radiother Oncol 2000; 57: 131-136. (Pubitemid 30774668)
31. Schmidt-Ullrich RK, Contessa JN, Dent P et al. Molecular mechanisms of radiation-induced accelerated repopulation. Radiat Oncol Investig 1999; 7: 321-330. (Pubitemid 30033351)
32. Bese NS, Hendry J, Jeremic B. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation. Int J Radiat Oncol Biol Phys 2007; 68: 654-661. (Pubitemid 46818766)
33. Coons SW, Johnson PC, Pearl DK. Prognostic significance of flow cytometry deoxyribonucleic acid analysis of human astrocytomas. Neurosurgery 1994; 35: 119-125; discussion 125-1116
34. Reavey-Cantwell JF, Haroun RI, Zahurak M et al. The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. J Neurooncol 2001; 55: 195-204. (Pubitemid 34134044)
35. van Rijn J, Heimans JJ, van den Berg J, van der Valk P, Slotman BJ. Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 2000; 47: 779-784.
36. Hirose Y, Berger MS, Pieper RO. Abrogation of the Chk1- mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res 2001; 61: 5843-5849.
37. Stupp R, Dietrich PY, Ostermann-Kraljevic S et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002; 20: 1375-1382. (Pubitemid 34177445)